Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2005

View Archived Issues

Therapeutic benefits of NSC-631570 in xeroderma pigmentosum

Improved barrier function found with lubiprostone in ischemia-injured intestine

Itopride improves gastric emptying in diabetic patients with gastroparesis

Preliminary phase II data on the antiviral efficacy of BIVN-401 in chronic hepatitis C

Interim data support the use of IDEA-033 in chronic pain

Favorable pharmacokinetic profile reported for ALTU-238 in healthy volunteers

CP-432 restores and adds bone mass in ovariectomized osteopenic rats

L-2286 reveals the cardioprotective effects of PARP inhibition

Novel approach for SARS treatment via RNA interference

Minerval - a novel compound and a new anticancer therapeutic strategy

Colostrinin evokes normalization of mitochondrial function

Iron chelator facilitates neurorescue

Positive opinion for oral iron chelator Exjade

XTL-6865 begins phase Ia study for HCV

Lilly to update Strattera label following reports of suicidal thoughts

Dr. Reddy's enters agreement with Rheoscience for balaglitazone

Phase II results for APF-530

Sirna Therapeutics and Allergan form strategic ophthalmology alliance

Myriad Genetics discovers COB1 gene for early-onset obesity

Eisai assumes development of Dainippon's AS-3201 for diabetic neuropathy

Takeda enters into agreement for Merck's matuzumab

German approval for Plenaxis

Sonus initiates pivotal study for Tocosol Paclitaxel for metastatic breast cancer

Mixed topline results for milnacipran in fibromyalgia

Pivotal phase III study of tesmilifene for breast cancer completes enrollment

Enrollment completed in phase II trial of AGI-001 for functional dyspepsia

New treatments for cancer covered in recent patents

Agents for arthritis in early development

Similar effects found for etilevodopa and levodopa in PD patients with motor fluctuations

Good efficacy and safety profile reported for R-411 in patients with moderate asthma

Bristol-Myers Squibb patent describes novel therapeutic agents for sarcopenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...